Differences in immune cell population subsets in inflammatory bowel disease patients under anti-TNF treatment

被引：0
|
作者：
Notararigo, S. [1 ,2 ]
Vinuela Roldan, J. E. [3 ]
Abanades-Tercero, M. [4 ]
Dominguez-Munoz, J. E. [1 ]
Barreiro-de Acosta, M. [1 ]
机构：
[1] Univ Hosp, Gastroenterol, Santiago De Compostela, Spain
[2] Fdn Ramon Dominguez, Santiago, Spain
[3] Univ Hosp, Immunol, Santiago, Spain
[4] Hosp Virgen Salud, Gastroenterol, Toledo, Spain
来源：
JOURNAL OF CROHNS & COLITIS | 2019年 / 13卷
关键词：
D O I：
10.1093/ecco-jcc/jjy222.186
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P062
引用
收藏
页码：S117 / S117
页数：1
相关论文
共 50 条
  • [41] Mucosal gene expression changes induced by anti-TNF treatment in inflammatory bowel disease patients
    Milanesi, Elena
    Dobre, Maria
    Manuc, Teodora E.
    Becheanu, Gabriel
    Tieranu, Cristian G.
    Ionescu, Elena M.
    Manuc, Mircea
    DRUG DEVELOPMENT RESEARCH, 2019, 80 (06) : 831 - 836
  • [42] The Relevance of Vitamin D and Antinuclear Antibodies in Patients with Inflammatory Bowel Disease Under Anti-TNF Treatment: A Prospective Study
    Santos-Antunes, Joao
    Nunes, Amadeu Corte-Real
    Lopes, Susana
    Macedo, Guilherme
    INFLAMMATORY BOWEL DISEASES, 2016, 22 (05) : 1101 - 1106
  • [43] Meta-Analysis on the Efficacy of a Second-Line Anti-TNF in Inflammatory Bowel Disease Patients With Failure to a Previous Anti-TNF Treatment
    Gisbert, Javier P.
    Marin, Alicia C.
    McNicholl, Adrian G.
    Chaparro, Maria
    GASTROENTEROLOGY, 2014, 146 (05) : S247 - S247
  • [44] Meta-analysis of the efficacy of a second-line anti-TNF in inflammatory bowel disease patients with failure to a previous anti-TNF treatment
    Gisbert, J. P.
    Marin, A.
    McNicholl, A.
    Chaparro, M.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S237 - S237
  • [45] Efficacy, safety and durability of anti-TNF therapy in the treatment of inflammatory bowel disease
    Trivedi, Chirag
    Kao, James
    Saxena, Mark
    Shen, Eric
    Das, Kiron
    Ebert, Ellen
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 : S448 - S448
  • [46] Anti-TNF treatment and renal cell carcinoma in patients with inflammatory bowel disease, rheumatoid arthritis and spondyloarthropathy: trigger or cure?
    Wauters, L.
    Joniau, S.
    Verschueren, P.
    Van Assche, G.
    Vermeire, S.
    Ferrante, M.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 : S395 - S396
  • [47] The effect of anti-TNF therapy on thyroid function in patients with inflammatory bowel disease
    Paschou, Stavroula A.
    Palioura, Eleni
    Kothonas, Fotios
    Myroforidis, Alexandros
    Loi, Vasiliki
    Poulou, Androniki
    Goumas, Konstantinos
    Effraimidis, Grigoris
    Vryonidou, Andromachi
    ENDOCRINE JOURNAL, 2018, 65 (11) : 1121 - 1125
  • [48] Tuberculosis and Immune Reconstitution Inflammatory Syndrome in Patients With Inflammatory Bowel Disease and Anti-TNFα Treatment: Insights From a French Multicenter Study and Systematic Literature Review With Emphasis on Paradoxical Anti-TNFα Resumption
    Amoura, Ariane
    Frapard, Thomas
    Treton, Xavier
    Surgers, Laure
    Beaugerie, Laurent
    Lafaurie, Matthieu
    Gornet, Jean Marc
    Lepeule, Raphael
    Amiot, Aurelien
    Canoui, Etienne
    Abitbol, Vered
    Froissart, Antoine
    Vidon, Mathias
    Nguyen, Yann
    Lefort, Agnes
    Zarrouk, Virginie
    OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (07):
  • [49] Onset of psoriasis in patients with inflammatory bowel disease treated with anti-TNF agents
    Guerra, Ivan
    Gisbert, Javier P.
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2013, 7 (01) : 41 - 48
  • [50] Effect of Anti-TNFα Therapy on Prevalence of Depression in Patients With Inflammatory Bowel Disease
    Loomes, Dustin E.
    Dittrich, Alexandra E.
    Madsen, Karen
    Dieleman, Levinus A.
    Halloran, Brendan P.
    Fedorak, Richard N.
    Kroeker, Karen I.
    GASTROENTEROLOGY, 2014, 146 (05) : S779 - S779
12345